TerminatedPhase 1

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

Stopped: Unable to recruit sufficient number of participants

United States3 participantsStarted 2008-12

Plain-language summary

Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose of this study is to determine whether potassium supplements and/or the medication acetazolamide affect the duration of muscle weakness and heart rhythm abnormalities in people with ATS.

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Neuromuscular Feature
✓. Cardiac Feature
✓. Physical Feature (at least two of the below five features)
✓OR-
✓OR-

What they're measuring

Sum of the attack durations across the entire treatment period, reported by the participants via interactive voice response (IVR)

Timeframe: Measured over two 18-week treatments periods

Trial details

NCT IDNCT00839501

SponsorUniversity of Rochester

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-01

View on ClinicalTrials.gov More Andersen-Tawil Syndrome trials